Lung Cancers Today

🫁Can combination benmelstobart and anlotinib improve survival in patients with PD-L1-positive advanced NSCLC compared with pembrolizumab monotherapy? 📋 Results from the phase 3 CAMPASS trial presented at #ASCO25 provided insights. ➡️ Learn more: buff.ly/ze3HA0i #lcsm

📰 With this week's announcement about #FLAURA2, we caught up with Pasi A. Jänne, MD, PhD, of @DanaFarber, who joined us to discuss the news about the final OS analysis of the phase 3 trial and what the future may hold. ➡️ Watch now: buff.ly/7SUmDbb #NSCLC #lcsm #EGFR

🫁 Catching up on #ASCO25 news? ⭐ Don't miss this insightful interview with @mollylisc on the LC-SHIELD study, which is evaluating AI-based lung cancer screening in people who have never smoked but are at a high risk for lung cancer. ➡️ Watch: buff.ly/PvgD9rw #lcsm

🫁 ICYMI: What's the latest on family history and lung cancer risk? ⭐ Don't miss this interview with Cheryl Czerlanis, MD, of @UWCarbone, who discusses her #ASCO25 presentation on the topic & what it may mean for lung cancer screening. ➡️ Watch: buff.ly/WZCzdxu #lcsm

📰 FLAURA2 UPDATE: Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement” in OS compared with osimertinib monotherapy for locally advanced or metastatic EGFR+ NSCLC. ➡️ Read more: buff.ly/cqx79mJ #NSCLC #EGFR #lcsm

🚴‍♂️ 🫁 How do updated evidence-based recommendations on exercise-based interventions improve mobility and general function in patients with lung cancer? ➡️ Learn what a recent systematic review showed: buff.ly/tIXSKLs #lcsm #NSCLC #LungCancersToday

🗨️ Catching up on podcasts this weekend? 🫁 Don't miss this candid discussion between @therealoncdoc & @lungoncdoc, who unpack a real patient case that illustrates key challenges in lung cancer care. ➡️ Listen to this episode of DDx: buff.ly/BbC0zoP #NSCLC #lcsm

💊 How will the accelerated approval of sunvozertinib shape the treatment landscape for EGFR+ #NSCLC? 🌟 In this new interview, @StephenVLiu, weighs in on the implications of the accelerated approval & what could be on the horizon. ➡️ Watch: buff.ly/LjnPRSp #lcsm

🗨️ ICYMI: Check out our interview with Ken Culver, MD, director of research and clinical affairs at @ALKPositiveinc, on the group's work at #ASCO25. “ALK Positive is a patient-led, patient-founded, and patient-run organization." ➡️ Watch now: buff.ly/0cbNVlp

🫁 Does savolitinib plus osimertinib improve survival in patients with MET-amplification EGFR-mutated NSCLC compared with chemotherapy? 💡 A recent study presented at #ASCO25 by a team of researchers from China addressed the question. ➡️ Learn more: buff.ly/PN6pbRL

Headed to the #ALKSummit25 today or tomorrow? Whether you’re a patient, care partner, researcher or clinician, you’ll find connection, info & hope in San Diego & online. Our planning committee looks fwd to seeing you. Let us know where your coming in from 👇 #StrongerTogether

Update to the @ASCO Living Guidelines for NSCLC without a driver alteration @JCO_ASCO from @dwightowenmd et al includes discussion on ivonescimab, the PD-1 / VEGF bispecific antibody, and the HARMONi-2 trial. Promising results but awaiting more data. ascopubs.org/doi/10.1200/JC…

🔥🚨HOT OFF THE PRESS Published @JCO_ASCO TWO @ASCO Living #Guideline updates Version 2025.1 by great experts on: Therapy for Stage IV Non-Small Cell #LungCancer: 1) WITHOUT Driver Alterations 👉 brnw.ch/21wUfz5 2) WITH Driver Alterations 👉 brnw.ch/21wUekt

Out now in @JCO_ASCO, v2025.1 of @ASCO Living Guideline for Stage 4 NSCLC w/ driver mutation. ascopubs.org/doi/pdf/10.120…. key updates: ✅incorporation of zenocutuzumab for NRG1-fusion+ NSCLC. ✅commentary on ph2 RAMOSE trial. For concise summary, ✔️ out @ASCO guidelines podcast

☀️ Editors at @Lung_Cancers spotlight a new podcast and expert interviews on key lung cancer topics: family history, virtual palliative care, and more. 🌍 As #WCLC25 approaches, they’re also reflecting on last year’s practice-changing findings. mashupmd.com/expert-collect…

🫁 How does stigma influence mental health in young adult patients with lung cancer? 💡 A study from a team of researchers in China and published in @jcansurv provided insights. ➡️ Read more: buff.ly/soc4giB #lcsm #NSCLC #lungcancer #LungCancersToday

📺 ICYMI: Check out our interview with @COlazagasti of @SylvesterCancer on all the highlights from #ASCO25, including insights on CheckMate-816, IMforte, DeLLphi-304, and more! ➡️Watch now: buff.ly/Zy2eHkZ #lcsm #NSCLC #ASCO25

🚨 Just out in @JTOonline! A must-read review from the @IASLC Communications Committee: 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic jto.org/article/S1556-… 🧭 A fast-track tour in #LungCancer, from staging to immunotherapy. Perfect to breathe in the past…

🫁 Check out our #ASCO25 interview with Shriya Garg of the University of Georgia and @EChrisDee of @MSKCancerCenter, covering their research on palliative intent lung cancer disparities in disaggregated Hispanic patient populations! ➡️ Learn more: buff.ly/z4glqqv #lcsm

Lung-MAP study of ctDNA from pts with NSCLC and matched tissue and plasma @CCR_AACR. Elevated ctDNA tumor fraction increased sensitivity of liquid biopsy but associated with worse survival. @LungMAP aacrjournals.org/clincancerres/…